New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Obinutuzumab significantly reduces disease activity in the most common form of lupus
10 March 2026
No Comments
Over three quarters of people on Obinutuzumab plus standard therapy achieved at least a